Indrayani Biotech Board of Directors

Get the latest insights into the leadership at Indrayani Biotech. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Nangavaram Mahadevan Ranganathan Chairman
Mr. Kasiraman Sayee Sundar Managing Director
Mr. Singarababu Indirakumar Director
Mr. G Swaminathan Director
Mr. Muthukrishnan Ramesh Director
Mr. Kannimangalam Subramanyan Vaidyanathan Director
Mrs. Lakshmiprabha Kasiraman Director
Dr. Bokara Nagarajan Padmaja Priyadarshini Director

Indrayani Biotech Share price

INDRANIB

12.29

0.09 (0.74%)
Last updated on 4 Sep, 2025 | 15:28 IST
BUYSELL
Today's High

12.72

Today's Low

11.60

52 Week Low

10.20

52 Week High

49.80

The current prices are delayed, login to your account for live prices

Indrayani Biotech FAQs

The board at Indrayani Biotech consists of experienced professionals, including Mr. Nangavaram Mahadevan Ranganathan , Mr. Kasiraman Sayee Sundar , and others, overseeing the company’s strategic and corporate governance.

Directors at Indrayani Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Nangavaram Mahadevan Ranganathan is the current chairman at Indrayani Biotech.

Executive directors at Indrayani Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Indrayani Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Indrayani Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.